



Endologix  
Investor Relations Department  
2 Musick  
Irvine, CA 92618  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: ELGX

Last Trade:	5.00
Trade Time:	4:00 PM ET Oct 17, 2017
Change:	-0.06 <span style="color: red;">↓</span> (-1.186%)
Day Range	4.98 - 5.07
52-Week Range	4.08 - 12.74
Volume	437,477

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

- Addressing a signi... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Oct 10, 2017  
[Endologix, Inc. to Announce Third Quarter 2017 Financial Results on November 7, 2017](#)

Oct 6, 2017  
[Endologix Receives IDE Approval for the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix® EndoVascular Aneurysm Sealing System](#)

Sep 21, 2017  
[Endologix Announces CE Mark Approval for the Nellix® EndoVascular Aneurysm Sealing System with the Refined Indications for Use](#)

Sep 11, 2017  
[Endologix Announces Collaboration Agreements with Japan Lifeline for the Development and Commercialization of Thoracic Endovascular Systems in Japan](#)

Aug 17, 2017  
[Endologix Announces Positive Clinical Results from the LEOPARD Clinical Study](#)

## Upcoming Events [\[ View all \]](#)

Nov 7, 2017 4:30 PM ET  
[Endologix 2017 Third Quarter Financial Results Conference Call](#)

## Financials [\[ View all \]](#)

### [Second Quarter Financial Results](#)

Mar 1, 2017  
[Annual Report \(10-K\)](#)

May 1, 2017  
[Proxy Statement \(DEF 14A\)](#)

Aug 4, 2017  
[Quarterly Report \(10-Q\)](#)

May 5, 2017  
[Quarterly Report \(10-Q\)](#)

Nov 8, 2016  
[Quarterly Report \(10-Q\)](#)